Evidence map›Paper›PMID 37836411›Full record

ArticleNutrients2023

Sclerostin, Osteocytes, and Wnt Signaling in Pediatric Renal Osteodystrophy.

Marciana Laster, Renata C Pereira, Kathleen Noche, Barbara Gales, Isidro B Salusky, Lauren V Albrecht

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Marciana LasterDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA.
Renata C PereiraDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA.
Kathleen NocheDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA.
Barbara GalesDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA.
Isidro B SaluskyDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA.
Lauren V AlbrechtDepartment of Pharmaceutical Sciences, School of Pharmacy, University of California, Irvine, CA 92697, USA.ORCID 0000-0002-3147-8010
University of California, Los Angeles · USUniversity of California, Irvine · US

Funding

Phosphate binder therapy and chronic kidney disease in childrenU01DK122013 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ISIDRO B. SALUSKY · 2020 to 2026
$10.8M
Regulation of Bone Mineralization in Renal OsteodystrophyR01DK035423 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SALUSKY, ISIDRO B. · 1986 to 2012
$4.9M
UCLA Clinical and Translational Science InstituteKL2TR000122 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$4.5M
ROLE OF PTH IN RENAL OSTEODYSTROPHYR01DK067563 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SALUSKY, ISIDRO B. · 2005 to 2009
$1.9M
Vitamin D Genetics and Racial Differences in Pediatric Chronic KidneyDisease-Mineral and Bone DisorderK23DK123378 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LASTER, MARCIANA LEE · 2020 to 2024
$995k
NCATS NIH HHS KL2 TR000122NIDDK NIH HHS DK-35423NIDDK NIH HHS DK-67563NIDDK NIH HHS K23 DK123378NIDDK NIH HHS K23-DK123378NIDDK NIH HHS NCATS UL1 TR000122NIDDK NIH HHS R01 DK035423NIDDK NIH HHS R01 DK067563NIDDK NIH HHS U01 DK122013NIDDK NIH HHS U01DK122013
6 · The paper itself

Abstract

The pathophysiology of chronic kidney disease-mineral and bone disorder (CKD-MBD) is not well understood. Specific factors secreted by osteocytes are elevated in the serum of adults and pediatric patients with CKD-MBD, including FGF-23 and sclerostin, a known inhibitor of the Wnt signaling pathway. The molecular mechanisms that promote bone disease during the progression of CKD are incompletely understood. In this study, we performed a cross-sectional analysis of 87 pediatric patients with pre-dialysis CKD and post-dialysis (CKD 5D). We assessed the associations between serum and bone sclerostin levels and biomarkers of bone turnover and bone histomorphometry. We report that serum sclerostin levels were elevated in both early and late CKD. Higher circulating and bone sclerostin levels were associated with histomorphometric parameters of bone turnover and mineralization. Immunofluorescence analyses of bone biopsies evaluated osteocyte staining of antibodies towards the canonical Wnt target, β-catenin, in the phosphorylated (inhibited) or unphosphorylated (active) forms. Bone sclerostin was found to be colocalized with phosphorylated β-catenin, which suggests that Wnt signaling was inhibited. In patients with low serum sclerostin levels, increased unphosphorylated "active" β-catenin staining was observed in osteocytes. These data provide new mechanistic insight into the pathogenesis of CKD-MBD and suggest that sclerostin may offer a potential biomarker or therapeutic target in pediatric renal osteodystrophy.

Indexed as

Chronic Kidney Disease-Mineral and Bone DisorderRenal Insufficiency, ChronicAdultbeta CateninBiomarkersChildCross-Sectional StudiesHumansOsteocytesWnt Signaling Pathwaybeta CateninBiomarkersbone biopsychildrenCKD-MBDimmunofluorescenceimmunohistochemistrysclerostinWnt signaling

Identifiers

PMID37836411
PMCPMC10574198
OpenAlexW4387020469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.